Orion and Aiforia extend collaboration to preclinical study evaluations
Thursday, March 06, 2025
Orion Corporation and Aiforia Technologies Plc, a Finnish medical software company, today announced the extension of their collaboration to include the use of Aiforia's software solution for preclinical study evaluations. This collaboration will involve implementing the Aiforia®Studies module within Orion's preclinical histology processes, as well as joint development to further automate and improve the study evaluation workflow of preclinical pathologists.
“We are thrilled to deepen our partnership with Aiforia; the Aiforia®Studies module aligns perfectly with our commitment to advancing pharmaceutical research and development. By leveraging Aiforia's AI-based image analysis and reporting tools, we expect faster and more efficient pathological evaluations, reducing the time required from pathologists to assess sample slides and improving the accuracy of our preclinical studies. We look forward to the valuable insights and advancements this partnership will bring,” says Riikka Oksala, Director, DMPK & Safety Sciences, R&D, Orion.
“We are extremely pleased to expand our collaboration with Orion. The Aiforia®Studies module is specifically designed for the needs of the pharmaceutical industry and their preclinical histology studies. It is exciting to collaborate with this innovative pharmaceutical company to gain valuable insights into their requirements and further develop our offering for this sector. Through this collaboration, we will strengthen our preclinical portfolio that already spans from the discovery phase to safety studies, and seamlessly integrates with our AI-based image analysis tools,” says Jukka Tapaninen, CEO, Aiforia.
Source: globenewswire.com
